Multidisciplinary Cancer Investigation

welcome

Multidisciplinary Cancer Investigation is a quarterly peer-reviewed journal focusing on all aspects of cancer research from bench to bedside. MCI aims to encourage comprehensive, multi-professional cancer research.

This journal is devoted to publishing substantial original studies with multidisciplinary approach in all areas of cancer research including basic and translational research, prevention, early detection, diagnosis, treatment, molecular and cellular biology, genetics, immunotherapy and regenerative medicine, biotechnology, epidemiology, psychological issues, rehabilitation, complementary and alternative medicine, medical ethics and law, informatics interventions, quality of life as well as novel engineering modalities in cancer therapy such as biomaterials, biophotonics, radiowave applications and bioelectronics medicine.

MCI received approval from the Commission for Accreditation & Improvement of Iranian Medical Journals according to certificate number 700/714 on 14 May 2017.

Main Image — Multidisciplinary Cancer Investigation

2022، Volume 6، Number 4

Print ISSN: 2476-4922

Electronic ISSN: 2538-1911

Editor-in-Chief: Keivan Majidzadeh-A

View The Current Issue

Successful Treatment of Monoclonal Gammopathy of Renal Significance With Bortezomib in the Setting of Post- Viral SARs-CoV-2 Infection: Case Report
Lauren McCroskie, Sarah Mahonski, Patrick D. Walker, Samir Dalia ^*
A Review of the Molecular Mechanisms of EGFR and IGFR Receptors in Tamoxifen Resistance in Breast Cancer
Sepideh Mansouri, Tannaz Samadi, Azin Teimurzadeh, Keivan Majidzadeh-A, Leila Farahmand ^*
The Prognostic Value of HER1 R497K in the Management of Patients with Breast Cancer
Masoomeh Baderi, Soodabeh ShahidSales, Kazem Anvari, Hassan Ramshini, Shima Mehrabadi, Abolfazal Nosrati Tirkani, Mehrane Mehramiz, Seyed Mahdi Hassanian, Amir Avan ^*

Successful Treatment of Monoclonal Gammopathy of Renal Significance With Bortezomib in the Setting of Post- Viral SARs-CoV-2 Infection: Case Report
Lauren McCroskie, Sarah Mahonski, Patrick D. Walker, Samir Dalia
The Prognostic Value of HER1 R497K in the Management of Patients with Breast Cancer
Masoomeh Baderi, Soodabeh ShahidSales, Kazem Anvari, Hassan Ramshini, Shima Mehrabadi, Abolfazal Nosrati Tirkani, Mehrane Mehramiz, Seyed Mahdi Hassanian, Amir Avan
A Review of the Molecular Mechanisms of EGFR and IGFR Receptors in Tamoxifen Resistance in Breast Cancer
Sepideh Mansouri, Tannaz Samadi, Azin Teimurzadeh, Keivan Majidzadeh-A, Leila Farahmand

[ 0-5 of 6 Next ]

Accepted Articles

Journal Information

Current Issue: 2022، Volume 6، Number 4
Print ISSN: 2476-4922
Electronic ISSN: 2538-1911
Editor-in-Chief: Keivan Majidzadeh-A
Publisher: Breast Cancer Recearch Center, ACECR

Indexing Databases

Index Copernicus
Google Scholar
SID
ISC
Magiran
Civilica
EZB
CiteFactor

Google Scholar

	All	Since 2018
Citations	433	402
h-index	10	10
i10-index	11	11

COVID-19 and impact on peer review

As a result of the significant disruption that is being caused by the COVID-19 pandemic, we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines, but we intend to be highly flexible at this time.

Site Statistics

Registered users: 602 users
Online users: 0 users
Guest users: 50 users
All visits: 3288918 visits
Visits in 24 Hours: 1353 visits

© 2023 CC BY-NC 4.0 | Multidisciplinary Cancer Investigation

Designed & Developed by : Yektaweb